Lily Dara, MD
Gastroenterology · Los Angeles, CANPI 1639325053
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $72,603 of the $80,247 with a category attached, or 90.5%. Intercept Pharmaceuticals, Inc. accounts for 87.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $70,052 and has fallen 85.7% since, to $10,022 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $2972.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$70K
- Agios Pharmaceuticals, Inc.$6K
- Ipsen Biopharmaceuticals, Inc$4K
- Madrigal Pharmaceuticals$83
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$78
What the payments were for
- Consulting fees$72,60390%
- Speaking & faculty fees$3,6725%
- Travel & lodging$3,0834%
- Food & beverage$8891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 12 | $70,147 |
| Agios Pharmaceuticals, Inc. | 8 | $5,953 |
| Ipsen Biopharmaceuticals, Inc | 5 | $3,986 |
| Madrigal Pharmaceuticals | 1 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $78 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,247 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $170 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Los Angeles
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$1.9M
- Sadeea AbbasiLos Angeles$556K
- Gil MelmedLos Angeles$467K
- Venkataraman MuthusamyLos Angeles$297K
- Caroline HwangLos Angeles$279K
- Adarsh ThakerLos Angeles$241K
- Andres YarurLos Angeles$218K
- Joseph PisegnaLos Angeles$210K
- Steven-Huy HanLos Angeles$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.